Dr. Susan Love's Breast Book: The Reference That Outlasted Its Own Editions

Dr. Susan Love's Breast Book was first published in 1990. Its author, Susan M. Love, is a breast surgeon and researcher whose career has focused on breast disease, and the book draws directly on that clinical practice.

Unlike most books in this series, it is not built around one story or one argument. It is a reference: a comprehensive guide to how the breast works, what can go wrong with it, and what a person facing any of those conditions, cancer among them, can expect from evaluation and treatment.

The book has been revised repeatedly since 1990, reaching a seventh edition in 2023. That revision history sets it apart from most books covered in this series, which reflect the medical understanding of a single year and do not get updated. This one has been kept current across more than three decades, which changes how carefully a reader needs to weight its specific screening and treatment guidance against how old their particular copy is.

Its scope is broader than cancer alone. It covers benign breast conditions, which are far more common than cancer and are a frequent source of anxiety when a lump or change is first noticed, alongside its cancer-specific chapters.

The book is organized by topic rather than by narrative arc. Early sections cover breast anatomy and normal changes across a lifetime, including puberty, pregnancy, breastfeeding and menopause. A substantial section addresses benign breast conditions: cysts, fibrocystic changes, mastitis and other non-cancerous findings, explaining how they are distinguished from cancer.

Cancer-specific sections cover screening, diagnosis, staging, and treatment options, organized to walk a reader through the sequence a diagnosis typically follows: an abnormal finding, further imaging, biopsy, pathology results, and then a discussion of treatment options depending on cancer type and stage.

Because the book has been revised across seven editions, later editions incorporate material that did not exist in 1990: genetic testing for BRCA1 and BRCA2, which were not identified as genes until the 1990s; targeted therapies developed since; and updated screening guidance reflecting decades of accumulated evidence.

The book also addresses topics adjacent to a diagnosis that a narrower clinical reference often skips: body image, sexuality after treatment, and navigating relationships and work during illness, reflecting its origin in a clinical practice that treated the whole patient, not only the pathology.

The book's greatest strength is its comprehensiveness and its willingness to cover benign conditions with the same care it gives cancer. A large share of readers who pick up a breast health book are dealing with a benign finding, not a cancer diagnosis, and a reference that treats that experience seriously, rather than treating everything short of cancer as a footnote, serves a real and common need.

Its authorship by a practicing breast surgeon gives it clinical grounding that a book written by a journalist or a patient alone would not have. The explanations of anatomy, diagnostic procedure and the logic behind treatment decisions reflect firsthand clinical experience.

Its ongoing revision is also a real strength relative to the other books in this category. Most books here are frozen at their publication year; this one has been updated repeatedly to reflect new genetics, new imaging and new treatment standards.

Even with seven editions, no printed book updates as fast as screening guidance can change. USPSTF revised its mammography recommendation in 2024, and any edition published before that revision will describe the prior, more individualized guidance for the 40-49 age range rather than the current straightforward biennial recommendation from age 40. A reader should check the copyright year of their specific copy and treat any screening age or interval in it as a starting point to verify against current guidance, not a final answer.

The book's genetic testing content is also edition-dependent. Genetic risk assessment, including which genes are tested and which professional societies recommend testing for whom, has expanded considerably since BRCA1 and BRCA2 were first identified, and older editions will not reflect the fuller current panel-testing landscape.

As with any long reference, the book's sheer length can also work against a reader in acute distress after a new diagnosis, who may need a narrower, more immediately actionable resource before returning to a comprehensive reference like this one.

The book covers breast cancer risk factors as part of its screening and prevention sections, and CDC's current material organizes that same information plainly.

CDC lists risk factors a person cannot change: growing older, inherited BRCA1 and BRCA2 mutations, early menstruation or late menopause, dense breast tissue, a personal history of breast cancer, a family history of breast or ovarian cancer, prior chest radiation, and DES exposure during pregnancy. It separately lists factors that can be changed: physical inactivity, weight gain after menopause, taking hormone replacement therapy for more than five years, certain oral contraceptives, and reproductive history factors such as having a first pregnancy after 30 or never breastfeeding. CDC also notes that alcohol consumption is a modifiable risk factor.

For people with a strong family history or a known BRCA mutation, CDC and NCI both point toward genetic counseling as the pathway to understanding personal risk and options, rather than a one-size guideline. NCI's own BRCA fact sheet reports that over 60 percent of women with a harmful BRCA mutation will develop breast cancer, compared with about 13 percent in the general population, underscoring why that group is evaluated differently from average-risk patients.

USPSTF currently recommends biennial screening mammography for women aged 40 to 74, a Grade B recommendation. This is the guidance current as of this writing; a reader relying on an older edition of this book should confirm their own copy reflects it, since USPSTF's prior guidance, in place for over a decade before the 2024 revision, treated the 40-49 age range as an individual decision rather than a blanket recommendation.

NCI's own screening material adds the balance of benefits and harms that both the book and USPSTF weigh in setting these recommendations: earlier detection can make treatment more effective, but false-positive results can cause distress and lead to unnecessary biopsies, and some cancers found through screening would not have needed treatment in a woman's lifetime, an overdiagnosis effect NCI states directly.

Women at higher risk, including those with a known BRCA mutation or strong family history, may be offered additional or earlier screening, including MRI, a decision made individually with a clinician rather than through the general population guideline. For the fuller current guidance, see breast cancer screening, breast cancer risk factors, and cancer screening overview for how breast screening fits alongside other recommended tests.

Comparing the book's earliest and most recent editions illustrates how much breast cancer care has changed since 1990. The first edition predates the identification of BRCA1 and BRCA2 as specific genes, predates targeted therapies such as HER2-directed treatment, which did not exist until the late 1990s, and predates the modern digital mammography and breast MRI technology used for high-risk screening today. Genetic counseling as a distinct, widely available clinical service also did not exist in its current form when the book was first written.

Later editions folded each of these developments in as they became established, which is part of why the book has remained a relevant reference rather than becoming a historical artifact the way most single-edition books from 1990 would have. Even so, the gap between any one edition and the present moment is real. A reader with a copy from even five or six years ago should treat its screening age, genetic testing panel, and targeted therapy sections as a foundation to update against current sources, not as a final word, because those are precisely the areas where practice has continued to move since even a fairly recent edition went to print.

This book suits a reader who wants a single, comprehensive reference to return to across a long process, whether that process involves a benign finding that needs monitoring, a new cancer diagnosis, or ongoing survivorship questions. Its breadth is a genuine advantage for that kind of sustained use.

It suits less well a reader who wants a quick answer to one urgent question, or the newest possible screening guidance without cross-checking, given how quickly that guidance can move relative to even a well-maintained book's revision cycle. For the most current screening ages and intervals, the source and links below reflect guidance current as of this writing.

Cancer Explained is free and ad-free, and you can support this work if it helped.

• Wikipedia — Susan Love
• USPSTF — Breast Cancer: Screening
• CDC — Breast Cancer Risk Factors
• NCI — BRCA Gene Changes: Cancer Risk and Genetic Testing
• NCI — Screening for Breast Cancer

This page discusses Dr. Susan Love's Breast Book for education. It is not medical advice, and nothing here is a judgement of anyone's real medical care.